At present there are multiple uncertainties concerning the clinical epidemiology, mechanisms of disease and management of cerebral venous thrombosis occurring after vaccination against COVID infection.
Upon notice of the first of these cases, the International Cerebral Venous Thrombosis Consortium designed, got ethical approval and launched an international prospective registry of cerebral venous thrombosis occurring after vaccination against COVID infection. Up to now approximately 50 cases were included from various hospitals across the world.
The International Cerebral Venous Thrombosis Consortium is a global collaboration by academic researchers with the primary aim to perform investigator-initiated research on cerebral venous thrombosis (CVT). Currently, 32 hospitals participate in the Consortium and we are hoping on increasing this number.
The aim of the study is to report clinical manifestations, laboratory findings, management, and outcome of patients with CVT after any COVID-19 vaccination.
The registry will include CVT patients with radiologically confirmed CVT, with onset of CVT symptoms within 4 weeks of COVID-19 vaccination, and informed consent.
Principal investigator is Jonathan Coutinho from the Amsterdam University Medical Centers (email@example.com)
Dr. Jonathan Coutinho, MD, PhD
Neurologist, Amsterdam University Medical Centers, location AMC, Department of Neurology | Room H2-260, Meibergdreef 9 | 1105 AZ Amsterdam | The Netherlands
Prof. Marcel Arnold, MD
Chairman / Chefarzt, Stroke Center, Department of Neurology, INSELSPITAL, University Hospital Bern, 3010 Bern, Switzerland
Prof. José M Ferro, MD, PhD
Full Professor of Neurology, Faculdade de Medicina, Universidade de Lisboa; Director Department of Neurosciences and Mental Health and Service of Neurology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
Prof. Turgut Tatlisumak, MD, PhD
Professor of Neurology and Stroke Medicine, University of Gothenburg, Gothenburg, Sweden